Get the Stockscreener App
0.811
1.12%
-0.0092
Pre-market:
.78
-0.031
-3.82%
Longeveron Inc stock is traded at $0.811, with a volume of 506.82K.
It is down -1.12% in the last 24 hours and down -13.72% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$0.8202
Open:
$0.8337
24h Volume:
506.82K
Relative Volume:
0.10
Market Cap:
$25.63M
Revenue:
$1.20M
Net Income/Loss:
$-22.70M
P/E Ratio:
-0.6236
EPS:
-1.3005
Net Cash Flow:
$-19.24M
1W Performance:
+20.45%
1M Performance:
-13.72%
6M Performance:
+25.25%
1Y Performance:
-39.93%
1-Day Range:
$0.7737
$0.85
1-Week Range:
$0.67
$0.85
52-Week Range:
$0.475
$1.80
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.811 | 25.92M | 1.20M | -22.70M | -19.24M | -1.3005 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
LGVN Should I Buy - Intellectia AI
Longeveron CEO outlines strategy ahead of August trial data By Investing.com - Investing.com Nigeria
Longeveron CEO outlines strategy ahead of August trial data - Investing.com
[ARS] Longeveron Inc. SEC Filing - Stock Titan
Longeveron (NASDAQ: LGVN) plans reverse split, bigger share pool and incentive plan - Stock Titan
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering ... - Caledonian Record
Inside Longeveron’s stem-cell push on a deadly infant heart defect - Stock Titan
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model - MSN
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift By Investing.com - Investing.com Nigeria
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift - Investing.com
[SCHEDULE 13G] Longeveron Inc. Passive Investment Disclosure (>5%) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Longeveron Earnings Call: Trial Milestones Amid FDA Hurdles - TipRanks
Longeveron Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript Summary - Moomoo
Longeveron Inc.Class A Common stock (NQ: LGVN - FinancialContent
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update - BioSpace
LGVN: Q1 2026 featured stable revenue, lower expenses, and a pivotal HLHS trial readout expected in August - TradingView
Longeveron Intends to Seek Additional Financing Opportunities, Capital Raises >LGVN - Moomoo
Longeveron (LGVN) Q1 2026 Earnings Transcript - AOL.com
LGVN: Cash runway extended into Q4 2026 as focus shifts to key HLHS trial results and regulatory milestones - TradingView
Earnings call transcript: Longeveron Q1 2026 shows stability amid challenges By Investing.com - Investing.com Canada
Longeveron Q1 2026 Earnings Call: Complete Transcript - Yahoo Finance
Longeveron Q1 revenue rises, beats analyst estimates - TradingView
Longeveron (NASDAQ: LGVN) Q1 2026 loss, cash jump and stem cell pipeline - Stock Titan
Longeveron (LGVN) boosts cash with financing but flags going-concern risk - Stock Titan
TradingKey - TradingKey
Longeveron Cut to Hold From Buy by Maxim Group - Moomoo
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Longeveron’s HLHS trial clears final safety review, data due August - Investing.com UK
LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Longeveron’s HLHS trial clears final safety review, data due August By Investing.com - Investing.com South Africa
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):